RPID · Insider Trading
Rapid Micro Biosystems, Inc. Class A Common Stock
Every open-market purchase and sale reported by RPID officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-24 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | M | +1,402 | +$1.05K |
| 2026-07-24 | Richard S Kollender | Director | M | +3,508 | +$2.63K |
| 2026-06-02 | Kirk Malloy | Director | A | +12,787 | +$25.00K |
| 2026-06-02 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | A | +12,787 | +$25.00K |
| 2026-06-02 | Melinda Litherland Pei | Director | A | +12,787 | +$25.00K |
| 2026-06-02 | Inese Lowenstein | Director | A | +12,787 | +$25.00K |
| 2026-06-02 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | A | +12,787 | +$25.00K |
| 2026-05-26 | Dafni Bika | Director | A | +19,300 | — |
| 2026-05-26 | Kirk Malloy | Director | A | +19,300 | — |
| 2026-05-26 | Richard S Kollender | Director | A | +19,300 | — |
| 2026-05-26 | Inese Lowenstein | Director | A | +19,300 | — |
| 2026-05-26 | Melinda Litherland Pei | Director | A | +19,300 | — |
| 2026-05-22 | Bain Capital Life Sciences Partners, LP | 10%+ Owner | Buy | — | — |
| 2026-03-12 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | Sell | −7,480 | −$32.30K |
| 2026-03-12 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | Sell | −17,922 | −$73.69K |
| 2026-03-12 | John J. Addington Wilson | CHIEF OPERATING OFFICER | Sell | −9,603 | −$41.47K |
| 2026-03-02 | Natale S Ricciardi | Director | M | +842 | +$632 |
| 2026-02-20 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | Sell | −17,254 | −$67.69K |
| 2026-02-20 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | Sell | −38,327 | −$148.91K |
| 2026-02-20 | John J. Addington Wilson | CHIEF OPERATING OFFICER | Sell | −5,403 | −$21.20K |
| 2026-02-13 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | A | +97,000 | — |
| 2026-02-13 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | A | +264,000 | — |
| 2026-02-13 | John J. Addington Wilson | CHIEF OPERATING OFFICER | A | +74,000 | — |
| 2026-02-10 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | Sell | −12,840 | −$48.57K |
| 2026-02-10 | John J. Addington Wilson | CHIEF OPERATING OFFICER | Sell | −4,610 | −$17.44K |
| 2026-02-10 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | Sell | −6,027 | −$22.80K |
| 2026-02-06 | Longitude Capital Partners II, LLC | 10%+ Owner | Sell | −294,000 | −$1.14M |
| 2026-02-03 | Longitude Capital Partners II, LLC | 10%+ Owner | MIXED | +2,601,465 | −$2.21M |
| 2025-11-18 | Kirk Malloy | Director | G | −40,000 | — |
| 2025-10-21 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | MIXED | +4,387 | −$12.66K |
| 2025-07-15 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | MIXED | +26,535 | −$78.98K |
| 2025-07-10 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | MIXED | +41,745 | −$116.98K |
| 2025-05-27 | Richard S Kollender | Director | A | +14,300 | — |
| 2025-05-27 | Kirk Malloy | Director | A | +14,300 | — |
| 2025-05-27 | Natale S Ricciardi | Director | A | +14,300 | — |
| 2025-05-27 | Melinda Litherland Pei | Director | A | +14,300 | — |
| 2025-05-27 | Inese Lowenstein | Director | A | +14,300 | — |
| 2025-05-27 | Dafni Bika | Director | A | +50,000 deriv. | — |
| 2025-03-11 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | F | −10,650 | −$25.45K |
| 2025-03-11 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | F | −7,690 | −$18.38K |
| 2025-03-11 | John J. Addington Wilson | CHIEF OPERATING OFFICER | F | −9,872 | −$23.59K |
| 2025-02-20 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | A | +365,000 | — |
| 2025-02-20 | John J. Addington Wilson | CHIEF OPERATING OFFICER | A | +44,000 | — |
| 2025-02-20 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | A | +160,000 | — |
| 2025-02-13 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | F | −4,621 | −$12.38K |
| 2025-02-13 | John J. Addington Wilson | CHIEF OPERATING OFFICER | F | −7,075 | −$18.96K |
| 2025-02-13 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | F | −10,755 | −$28.82K |
| 2025-02-07 | Sean M Wirtjes | CHIEF FINANCIAL OFFICER | F | −5,891 | −$18.26K |
| 2025-02-07 | Robert G. Spignesi Jr. | PRESIDENT AND CEO | F | −13,052 | −$40.46K |
| 2025-02-07 | John J. Addington Wilson | CHIEF OPERATING OFFICER | F | −4,505 | −$13.97K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bain Capital Life Sciences Partners, LP | 10%+ Owner | 8,434,560 | $6.62M |
| Longitude Capital Partners II, LLC | 10%+ Owner | 4,029,245 | $3.16M |
| Richard S Kollender | Director | 1,614,835 | $1.27M |
| Robert G. Spignesi Jr. | PRESIDENT AND CEO | 1,191,973 | $935.70K |
| Sean M Wirtjes | CHIEF FINANCIAL OFFICER | 568,981 | $446.65K |
| John J. Addington Wilson | CHIEF OPERATING OFFICER | 316,762 | $248.66K |
| Melinda Litherland Pei | Director | 100,687 | $79.04K |
| Kirk Malloy | Director | 70,687 | $55.49K |
| Inese Lowenstein | Director | 70,687 | $55.49K |
| Natale S Ricciardi | Director | 29,442 | $23.11K |
| Dafni Bika | Director | 19,300 | $15.15K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RPID quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.